103 related articles for article (PubMed ID: 15991444)
1. Architectures of genetic medicine: comparing genetic testing for breast cancer in the USA and the UK.
Parthasarathy S
Soc Stud Sci; 2005 Feb; 35(1):5-40. PubMed ID: 15991444
[TBL] [Abstract][Full Text] [Related]
2. Direct to confusion: lessons learned from marketing BRCA testing.
Matloff E; Caplan A
Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
[TBL] [Abstract][Full Text] [Related]
3. BRCA patients and clinical collectives: new configurations of action in cancer genetics practices.
Bourret P
Soc Stud Sci; 2005 Feb; 35(1):41-68. PubMed ID: 15991445
[TBL] [Abstract][Full Text] [Related]
4. The patent is political: the consequences of patenting the BRCA genes in Britain.
Parthasarathy S
Community Genet; 2005; 8(4):235-42. PubMed ID: 16244478
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
6. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
Lee R; Beattie M; Crawford B; Mak J; Stewart N; Komaromy M; Esserman L; Shaw L; McLennan J; Strachowski L; Luce J; Ziegler J
Genet Test; 2005; 9(4):306-12. PubMed ID: 16379544
[TBL] [Abstract][Full Text] [Related]
7. Unambiguous test results or individual independence? The role of clients and families in predictive BRCA-testing in the Netherlands compared to the USA.
Boenink M
Soc Sci Med; 2011 Jun; 72(11):1793-801. PubMed ID: 20650557
[TBL] [Abstract][Full Text] [Related]
8. Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine.
Mackay J; Taylor A
Breast; 2006 Dec; 15 Suppl 2():S65-70. PubMed ID: 17382866
[TBL] [Abstract][Full Text] [Related]
9. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
10. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
Paradise J
Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
[No Abstract] [Full Text] [Related]
11. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Evans DG; Harkness E; Lalloo F; Howell A
J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
[TBL] [Abstract][Full Text] [Related]
12. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
[TBL] [Abstract][Full Text] [Related]
13. A UK collaborative 1-day pilot information and support forum facilitated by a national breast cancer charity and NHS cancer genetic counsellors, for women at high risk, BRCA 1/2 gene carriers and hereditary breast cancer.
Harris J; Ward S
Eur J Cancer Care (Engl); 2011 Nov; 20(6):818-24. PubMed ID: 21838724
[TBL] [Abstract][Full Text] [Related]
14. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
Silva E; Lynch H
Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
[No Abstract] [Full Text] [Related]
15. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
Trivers KF; Baldwin LM; Miller JW; Matthews B; Andrilla CH; Lishner DM; Goff BA
Cancer; 2011 Dec; 117(23):5334-43. PubMed ID: 21792861
[TBL] [Abstract][Full Text] [Related]
16. "Be ready against cancer, now": direct-to-consumer advertising for genetic testing.
William-Jones B
New Genet Soc; 2006 Apr; 25(1):89-107. PubMed ID: 17312631
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
18. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Peterson EA; Milliron KJ; Lewis KE; Goold SD; Merajver SD
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):79-87. PubMed ID: 11815404
[TBL] [Abstract][Full Text] [Related]
19. Myriad Genetics embroiled in breast-cancer data fight - again.
Check Hayden E
Nature; 2016 May; 533(7604):449. PubMed ID: 27225096
[No Abstract] [Full Text] [Related]
20. BRCA1/2 genetic testing in the community setting.
Chen WY; Garber JE; Higham S; Schneider KA; Davis KB; Deffenbaugh AM; Frank TS; Gelman RS; Li FP
J Clin Oncol; 2002 Nov; 20(22):4485-92. PubMed ID: 12431973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
